105 related articles for article (PubMed ID: 9737663)
21. Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.
Low HZ; Hilbrans D; Schmidt-Wolf IG; Illges H
Int J Hematol; 2012 Sep; 96(3):350-6. PubMed ID: 22899340
[TBL] [Abstract][Full Text] [Related]
22. Age-related depression of FDC accessory functions and CD21 ligand-mediated repair of co-stimulation.
Aydar Y; Balogh P; Tew JG; Szakal AK
Eur J Immunol; 2002 Oct; 32(10):2817-26. PubMed ID: 12355434
[TBL] [Abstract][Full Text] [Related]
23. The role of the Epstein-Barr virus receptor CD21 in multiple sclerosis.
Toepfner N; Cepok S; Grummel V; Hemmer B
J Neuroimmunol; 2012 Jan; 242(1-2):47-51. PubMed ID: 22137275
[TBL] [Abstract][Full Text] [Related]
24. Follicular dendritic cell accessory activity crosses MHC and species barriers.
Fakher M; Wu J; Qin D; Szakal A; Tew J
Eur J Immunol; 2001 Jan; 31(1):176-85. PubMed ID: 11169451
[TBL] [Abstract][Full Text] [Related]
25. Characterization of an Epstein-Barr virus receptor on human epithelial cells.
Birkenbach M; Tong X; Bradbury LE; Tedder TF; Kieff E
J Exp Med; 1992 Nov; 176(5):1405-14. PubMed ID: 1383386
[TBL] [Abstract][Full Text] [Related]
26. Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis.
Masilamani M; Nowack R; Witte T; Schlesier M; Warnatz K; Glocker MO; Peter HH; Illges H
Scand J Immunol; 2004 Dec; 60(6):625-30. PubMed ID: 15584974
[TBL] [Abstract][Full Text] [Related]
27. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.
Nichols EM; Jones R; Watson R; Pepper CJ; Fegan C; Marchbank KJ
Oncotarget; 2015 Oct; 6(32):32669-80. PubMed ID: 26452134
[TBL] [Abstract][Full Text] [Related]
28. Ligation of the functional domain of complement receptor type 2 (CR2, CD21) is relevant for complex formation in T cell lines.
Prodinger WM; Larcher C; Schwendinger M; Dierich MP
J Immunol; 1996 Apr; 156(7):2580-4. PubMed ID: 8786322
[TBL] [Abstract][Full Text] [Related]
29. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
30. A subset of anti-CD21 antibodies promote the rescue of germinal center B cells from apoptosis.
Bonnefoy JY; Henchoz S; Hardie D; Holder MJ; Gordon J
Eur J Immunol; 1993 Apr; 23(4):969-72. PubMed ID: 8458382
[TBL] [Abstract][Full Text] [Related]
31. Genetic CD21 deficiency is associated with hypogammaglobulinemia.
Thiel J; Kimmig L; Salzer U; Grudzien M; Lebrecht D; Hagena T; Draeger R; Voelxen N; Bergbreiter A; Jennings S; Gutenberger S; Aichem A; Illges H; Hannan JP; Kienzler AK; Rizzi M; Eibel H; Peter HH; Warnatz K; Grimbacher B; Rump JA; Schlesier M
J Allergy Clin Immunol; 2012 Mar; 129(3):801-810.e6. PubMed ID: 22035880
[TBL] [Abstract][Full Text] [Related]
32. Relationship between reactive nitrogen intermediates and total immunoglobulin E, soluble CD21 and soluble CD23: comparison between cerebral malaria and nonsevere malaria.
Nacher M; Singhasivanon P; Kaewkungwal J; Silachamroon U; Treeprasertsuk S; Tosukhowong T; Vannaphan S; Looareesuwan S
Parasite Immunol; 2002 Aug; 24(8):395-9. PubMed ID: 12406193
[TBL] [Abstract][Full Text] [Related]
33. Expression of CD21 and CD23 during human fetal development.
Thornton CA; Holloway JA; Warner JO
Pediatr Res; 2002 Aug; 52(2):245-50. PubMed ID: 12149502
[TBL] [Abstract][Full Text] [Related]
34. CD21 augments antigen presentation in immune individuals.
Boackle SA; Holers VM; Karp DR
Eur J Immunol; 1997 Jan; 27(1):122-9. PubMed ID: 9022008
[TBL] [Abstract][Full Text] [Related]
35. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
36. CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell lines to specific CD4+ T cell clones.
Grosjean I; Lachaux A; Bella C; Aubry JP; Bonnefoy JY; Kaiserlian D
Eur J Immunol; 1994 Dec; 24(12):2982-6. PubMed ID: 7805725
[TBL] [Abstract][Full Text] [Related]
37. T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression.
Masilamani M; von Seydlitz E; Bastmeyer M; Illges H
Immunobiology; 2002 Dec; 206(5):528-36. PubMed ID: 12607728
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins.
Rayhel EJ; Dehoff MH; Holers VM
J Immunol; 1991 Mar; 146(6):2021-6. PubMed ID: 1706386
[TBL] [Abstract][Full Text] [Related]
39. Stable expression and function of EBV/C3d receptor following genomic transfection into murine fibroblast L cells.
Cantaloube JF; Piechaczyk M; Calender A; Lenoir G; Minty A; Carrière D; Fischer E; Poncelet P
Eur J Immunol; 1990 Feb; 20(2):409-16. PubMed ID: 1690137
[TBL] [Abstract][Full Text] [Related]
40. T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE).
Levy E; Ambrus J; Kahl L; Molina H; Tung K; Holers VM
Clin Exp Immunol; 1992 Nov; 90(2):235-44. PubMed ID: 1424280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
